{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:55:52Z","timestamp":1773662152066,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s11255-020-02656-y","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T17:06:45Z","timestamp":1603818405000},"page":"749-761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The effect of anemia on the efficacy and safety of treating chronic hepatitis C infection with direct-acting antivirals in patients with chronic kidney disease"],"prefix":"10.1007","volume":"53","author":[{"given":"Ahmed Yahia","family":"Elmowafy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Hamed","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Abdelfattah","family":"Denewar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Elsayed","family":"Mashaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamal","family":"Shiha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salwa Mahmoud","family":"El Wasif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5130-7286","authenticated-orcid":false,"given":"Lionel","family":"Rostaing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Adel","family":"Bakr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"2656_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4254\/wjh.v7.i1.78","volume":"7","author":"AN Azmi","year":"2015","unstructured":"Azmi AN, Tan SS, Mohamed R (2015) Hepatitis C and kidney disease: an overview and approach to management. World J Hepatol 7:78\u201392. https:\/\/doi.org\/10.4254\/wjh.v7.i1.78","journal-title":"World J Hepatol"},{"key":"2656_CR2","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/hep.27664","volume":"61","author":"MZ Molnar","year":"2015","unstructured":"Molnar MZ, Alhourani HM, Wall BM, Lu JL, Streja E, Kalantar-Zadeh K, Kovesdy CP (2015) Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology 61:1495\u20131502. https:\/\/doi.org\/10.1002\/hep.27664","journal-title":"Hepatology"},{"key":"2656_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.clinre.2018.10.009","volume":"43","author":"F Fabrizi","year":"2019","unstructured":"Fabrizi F, Dixit V, Messa P (2019) Hepatitis C virus and mortality among patients on dialysis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 43:244\u2013254. https:\/\/doi.org\/10.1016\/j.clinre.2018.10.009","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2656_CR4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1365-2893.2012.01633.x","volume":"19","author":"F Fabrizi","year":"2012","unstructured":"Fabrizi F, Dixit V, Messa P (2012) Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat 19:601\u2013607. https:\/\/doi.org\/10.1111\/j.1365-2893.2012.01633.x","journal-title":"J Viral Hepat"},{"key":"2656_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/hep4.1035","volume":"1","author":"P Cox-North","year":"2017","unstructured":"Cox-North P, Hawkins KL, Rossiter ST, Hawley MN, Bhattacharya R, Landis CS (2017) Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. Hepatol Commun 1:248\u2013255. https:\/\/doi.org\/10.1002\/hep4.1035","journal-title":"Hepatol Commun"},{"key":"2656_CR6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","volume":"54","author":"BJ Kirby","year":"2015","unstructured":"Kirby BJ, Symonds WT, Kearney BP, Mathias AA (2015) Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet 54:677\u2013690. https:\/\/doi.org\/10.1007\/s40262-015-0261-7","journal-title":"Clin Pharmacokinet"},{"key":"2656_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","volume":"151","author":"JM Pawlotsky","year":"2016","unstructured":"Pawlotsky JM (2016) Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 151:70\u201386. https:\/\/doi.org\/10.1053\/j.gastro.2016.04.003","journal-title":"Gastroenterology"},{"key":"2656_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00228-018-2566-6","volume":"75","author":"DL Shuster","year":"2019","unstructured":"Shuster DL, Menon RM, Ding B, Khatri A, Li H, Cohen E, Jewett M, Cohen DE, Zha J (2019) Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials. Eur J Clin Pharmacol 75:207\u2013216. https:\/\/doi.org\/10.1007\/s00228-018-2566-6","journal-title":"Eur J Clin Pharmacol"},{"key":"2656_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1681\/ASN.2007070728","volume":"20","author":"K Kalantar-Zadeh","year":"2009","unstructured":"Kalantar-Zadeh K, Aronoff GR (2009) Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol 20:479\u2013487. https:\/\/doi.org\/10.1681\/ASN.2007070728","journal-title":"J Am Soc Nephrol"},{"key":"2656_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1681\/ASN.2007070728","volume":"368","author":"EJ Gane","year":"2013","unstructured":"Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM (2013) Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368:34\u201344. https:\/\/doi.org\/10.1681\/ASN.2007070728","journal-title":"N Engl J Med"},{"key":"2656_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3346\/jkms.2017.32.2.249","volume":"32","author":"SR Ryu","year":"2017","unstructured":"Ryu SR, Park SK, Jung JY, Kim YH, Oh YK, Yoo TH, Sung S (2017) The prevalence and management of anemia in chronic kidney disease patients: result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). J Korean Med Sci 32:249\u2013256. https:\/\/doi.org\/10.3346\/jkms.2017.32.2.249","journal-title":"J Korean Med Sci"},{"key":"2656_CR12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0399-8320(07)89420-6","volume":"31","author":"H Fontaine","year":"2007","unstructured":"Fontaine H, Petitprez K, Roudot-Thoraval F, Trinchet JC (2007) Guidelines for the diagnosis of uncomplicated cirrhosis. Gastroent\u00e9rologie clinique et biologique 31:504","journal-title":"Gastroent\u00e9rologie clinique et biologique"},{"key":"2656_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jhep.2010.10.018","volume":"55","author":"E Tr\u00e9po","year":"2011","unstructured":"Tr\u00e9po E, Potthoff A, Pradat P, Bakshi R, Young B, Lagier R, Moreno R, Verset L, Cross R, Degr\u00e9 D, Lemmers A, Gustot T, Berthillon P, Rosenberg W, Tr\u00e9po C, Sninsky J, Adler M, Wedemeyer H (2011) Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol 55:38\u201344. https:\/\/doi.org\/10.1016\/j.jhep.2010.10.018","journal-title":"J Hepatol"},{"key":"2656_CR14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cyto.2017.10.026","volume":"106","author":"A Biswas","year":"2018","unstructured":"Biswas A, Gupta N, Gupta D, Datta A, Firdaus R, Chowdhury P, Bhattacharyya M, Sadhukhan PC (2018) Association of TNF-alpha (\u2212 308 A\/G) and IFN-gamma (+ 874 A\/T) gene polymorphisms in response to spontaneous and treatment induced viral clearance in HCV infected multitransfused thalassemic patients. Cytokine 106:148\u2013153. https:\/\/doi.org\/10.1016\/j.cyto.2017.10.026","journal-title":"Cytokine"},{"key":"2656_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2016","unstructured":"Polaris Observatory HCV Collaborators (2016) Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2:161\u2013176. https:\/\/doi.org\/10.1016\/S2468-1253(16)30181-9","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2656_CR16","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.kint.2018.11.038","volume":"95","author":"M Jadoul","year":"2019","unstructured":"Jadoul M, Bieber BA, Martin P, Akiba T, Nwankwo C, Arduino JM, Goodkin DA, Pisoni RL (2019) Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int 95:939\u2013947. https:\/\/doi.org\/10.1016\/j.kint.2018.11.038","journal-title":"Kidney Int"},{"key":"2656_CR17","first-page":"139","volume":"66","author":"F Fabrizi","year":"2014","unstructured":"Fabrizi F, Donato F, Messa P (2014) Hepatitis C virus infection and glomerular disease. Minerva Urol Nefrol 66:139\u2013149","journal-title":"Minerva Urol Nefrol"},{"key":"2656_CR18","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/TP.0b013e3181837761","volume":"86","author":"CJ Hoffmann","year":"2008","unstructured":"Hoffmann CJ, Subramanian AK, Cameron AM, Engels EA (2008) Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation. Transplantation 86:784\u2013790. https:\/\/doi.org\/10.1097\/TP.0b013e3181837761","journal-title":"Transplantation"},{"key":"2656_CR19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/TP.0000000000001953","volume":"102","author":"NY Heo","year":"2018","unstructured":"Heo NY, Mannalithara A, Kim D, Udompap P, Tan JC, Kim WR (2018) Long-term patient and graft survival of kidney transplant recipients with Hepatitis C virus infection in the United States. Transplantation 102:454\u2013460. https:\/\/doi.org\/10.1097\/TP.0000000000001953","journal-title":"Transplantation"},{"key":"2656_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/ndt\/gfx281","volume":"33","author":"AH Santos Jr","year":"2018","unstructured":"Santos AH Jr, Chen C, Casey MJ, Womer KL, Wen X (2018) New-onset diabetes after kidney transplantation: can the risk be modified by choosing immunosuppression regimen based on pretransplant viral serology? Nephrol Dial Transpl 33:177\u2013184. https:\/\/doi.org\/10.1093\/ndt\/gfx281","journal-title":"Nephrol Dial Transpl"},{"key":"2656_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2174\/1871526518666180716141806","volume":"20","author":"EA Wahsh","year":"2020","unstructured":"Wahsh EA, Hussein AK, Gomaa AA, Baraka MA, Al-Deen Abead M (2020) Real life Egyptian experience of daclatasvir plus sofosbuvir with Ribavirin in Na\u00efve difficult to treat HCV patients. Infect Disord Drug Targets 20:43\u201348. https:\/\/doi.org\/10.2174\/1871526518666180716141806","journal-title":"Infect Disord Drug Targets"},{"key":"2656_CR22","unstructured":"AASLD (2016) HCV guidance: recommendations for testing, managing, and treating hepatitis C. https:\/\/www.hcvguidelines.org\/"},{"key":"2656_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/liv.13102","volume":"36","author":"V Saxena","year":"2016","unstructured":"Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, Liapakis A, Nelson DR, Fried MW, Terrault NA, HCV-TARGET, (2016) Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 36:807\u2013816. https:\/\/doi.org\/10.1111\/liv.13102","journal-title":"Liver Int"},{"key":"2656_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","volume":"65","author":"A Desnoyer","year":"2016","unstructured":"Desnoyer A, Pospai D, L\u00ea MP, Gervais A, Heurgu\u00e9-Berlot A, Laradi A, Harent S, Pinto A, Salmon D, Hillaire S, Fontaine H, Zucman D, Simonpoli AM, Muret P, Larrouy L, Bernard Chabert B, Descamps D, Yazdanpanah Y, Peytavin G (2016) Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 65:40\u201347. https:\/\/doi.org\/10.1016\/j.jhep.2016.02.044","journal-title":"J Hepatol"},{"key":"2656_CR25","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s40262-019-00774-0","volume":"58","author":"EJ Smolders","year":"2019","unstructured":"Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM (2019) Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations: a 2019 update. Clin Pharmacokinet 58:1237\u20131263. https:\/\/doi.org\/10.1007\/s40262-019-00774-0 (PMID: 31114957)","journal-title":"Clin Pharmacokinet"},{"key":"2656_CR26","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1007\/s11255-019-02316-w","volume":"51","author":"AY Elmowafy","year":"2019","unstructured":"Elmowafy AY, El Maghrabi HM, Mashaly ME, Eldahshan KF, Rostaing L, Bakr MA (2019) High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents. Int Urol Nephrol 51:2243\u20132254. https:\/\/doi.org\/10.1007\/s11255-019-02316-w","journal-title":"Int Urol Nephrol"},{"key":"2656_CR27","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s11255-019-02246-7","volume":"51","author":"AY Elmowafy","year":"2019","unstructured":"Elmowafy AY, El Maghrabi HM, Eldahshan KF, Refaie AF, Elbasiony MA, Matter YE, Saleh HH, Shiha GE, Rostaing L, Bakr MA (2019) Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality. Int Urol Nephrol 51:1639\u20131647. https:\/\/doi.org\/10.1007\/s11255-019-02246-7","journal-title":"Int Urol Nephrol"},{"key":"2656_CR28","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s11255-019-02272-5","volume":"51","author":"HME Maghrabi","year":"2019","unstructured":"Maghrabi HME, Elmowafy AY, Refaie AF, Elbasiony MA, Shiha GE, Rostaing L, Bakr MA (2019) Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients. Int Urol Nephrol 51:2295\u20132304. https:\/\/doi.org\/10.1007\/s11255-019-02272-5","journal-title":"Int Urol Nephrol"},{"key":"2656_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.kint.2019.04.030","volume":"97","author":"ME Sise","year":"2020","unstructured":"Sise ME, Chute DF, Oppong Y, Davis MI, Long JD, Silva ST, Rusibamayila N, Jean-Francois D, Raji S, Zhao S, Thadhani R, Chung RT (2020) Direct-acting antiviral therapy slows kidney function decline in patients with hepatitis C virus infection and chronic kidney disease. Kidney Int 97:193\u2013201. https:\/\/doi.org\/10.1016\/j.kint.2019.04.030","journal-title":"Kidney Int"},{"key":"2656_CR30","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/tri.12799","volume":"29","author":"S Beinhardt","year":"2016","unstructured":"Beinhardt S, Al Zoairy R, Ferenci P, Kozbial K, Freissmuth C, Stern R, St\u00e4ttermayer AF, Stauber R, Strasser M, Zoller H, Watschinger B, Watschinger B, Schmidt A, Trauner M, Hofer H, Maieron A (2016) DAA-based antiviral treatment of patients with chronic hepatitis C in the pre-and postkidney transplantation setting. Transpl Inter 29:999\u20131007. https:\/\/doi.org\/10.1111\/tri.12799","journal-title":"Transpl Inter"},{"key":"2656_CR31","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/ajt.13620","volume":"16","author":"D Sawinski","year":"2016","unstructured":"Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, Bleicher M, Goral S, Forde KA, Bloom RD (2016) Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transpl 16:1588\u20131595. https:\/\/doi.org\/10.1111\/ajt.13620","journal-title":"Am J Transpl"},{"key":"2656_CR32","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/nep.13109","volume":"23","author":"S Taneja","year":"2018","unstructured":"Taneja S, Duseja A, De A, Kumar V, Ramachandran R, Sharma A, Dhiman RK, Gupta KL, Chawla Y (2018) Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients. Nephrology 23:876\u2013882. https:\/\/doi.org\/10.1111\/nep.13109","journal-title":"Nephrology"},{"key":"2656_CR33","doi-asserted-by":"publisher","first-page":"7579689","DOI":"10.1155\/2018\/7579689","volume":"2018","author":"S Sharma","year":"2018","unstructured":"Sharma S, Mukherjee D, Nair RK, Datt B, Rao A (2018) Role of direct antiviral agents in treatment of chronic hepatitis C infection in renal transplant recipients. J Transpl 2018:7579689. https:\/\/doi.org\/10.1155\/2018\/7579689","journal-title":"J Transpl"},{"key":"2656_CR34","volume-title":"StatPearls","author":"H Shaikh","year":"2020","unstructured":"Shaikh H, Aeddula NR (2020) Anemia of chronic renal disease. StatPearls. StatPearls Publishing, Treasure Island"},{"key":"2656_CR35","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/ki.2012.270","volume":"82","author":"TB Dr\u00fceke","year":"2012","unstructured":"Dr\u00fceke TB, Parfrey PS (2012) Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int 82:952\u2013960. https:\/\/doi.org\/10.1038\/ki.2012.270","journal-title":"Kidney Int"},{"key":"2656_CR36","doi-asserted-by":"publisher","first-page":"e0158512","DOI":"10.1371\/journal.pone.0158512","volume":"7","author":"T Kuntzen","year":"2016","unstructured":"Kuntzen T, Kuhn S, Kuntzen D, Seifert B, M\u00fcllhaupt B, Geier A (2016) Influence of ribavirin serum levels on outcome of antiviral treatment and anemia in hepatitis C virus infection. PLoS ONE 7:e0158512. https:\/\/doi.org\/10.1371\/journal.pone.0158512","journal-title":"PLoS ONE"},{"key":"2656_CR37","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1111\/liv.13708","volume":"38","author":"JJ Feld","year":"2018","unstructured":"Feld JJ, Bernstein DE, Younes Z, Vlierberghe HV, Larsen L, Tatsch F, Ferenci P (2018) Ribavirin dose management in HCV patients receiving ombitasvir\/paritaprevir\/ritonavir and dasabuvir with ribavirin. Liver Int 38:1571\u20131575. https:\/\/doi.org\/10.1111\/liv.13708","journal-title":"Liver Int"},{"key":"2656_CR38","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/hepr.13311","volume":"49","author":"M Nakashima","year":"2019","unstructured":"Nakashima M, Toyoda H, Tada T, Mizuno K, Iio E, Tanaka Y, Sugiyama T, Yoshimura T, Kumada T (2019) Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and all-oral direct acting antivirals in patients with chronic hepatitis C virus infection. Hepatol Res 49:512\u2013520. https:\/\/doi.org\/10.1111\/hepr.13311","journal-title":"Hepatol Res"},{"key":"2656_CR39","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","volume":"150","author":"PJ Pockros","year":"2016","unstructured":"Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, Bernstein DE, Cohen DE, Shulman NS, Wang D, Khatri A, Abunimeh M, Podsadecki T, Lawitz E (2016) Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 150:1590\u20131598. https:\/\/doi.org\/10.1053\/j.gastro.2016.02.078","journal-title":"Gastroenterology"},{"key":"2656_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.23736\/S0375-9393.18.12257-7","volume":"85","author":"R Callejas","year":"2019","unstructured":"Callejas R, Panadero A, Vives M, Duque P, Echarri G, Monedero P (2019) Renal Dysfunction in Cardiac Surgery Spanish Group (GEDRCC2). Preoperative predictive model for acute kidney injury after elective cardiac surgery: a prospective multicenter cohort study. Minerva Anestesiol 85:34\u201344. https:\/\/doi.org\/10.23736\/S0375-9393.18.12257-7","journal-title":"Minerva Anestesiol"},{"key":"2656_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz087","author":"N Srisawat","year":"2019","unstructured":"Srisawat N, Kulvichit W, Mahamitra N, Hurst C, Praditpornsilpa K, Lumlertgul N, Chuasuwan A, Trongtrakul K, Tasnarong A, Champunot R, Bhurayanontachai R, Kongwibulwut M, Chatkaew P, Oranrigsupak P, Sukmark T, Panaput T, Laohacharoenyot N, Surasit K, Keobounma T, Khositrangsikun K, Suwattanasilpa U, Pattharanitima P, Santithisadeekorn P, Wanitchanont A, Peerapornrattana S, Loaveeravat P, Leelahavanichkul A, Tiranathanagul K, Kerr SJ, Tungsanga K, Eiam-Ong S, Sitprija V, Kellum JA (2019) The epidemiology and characteristics of acute kidney injury in the Southeast Asia intensive care unit: a prospective multicentre study. Nephrol Dial Transpl. https:\/\/doi.org\/10.1093\/ndt\/gfz087","journal-title":"Nephrol Dial Transpl"},{"key":"2656_CR42","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10157-018-1649-0","volume":"23","author":"T Hayashi","year":"2019","unstructured":"Hayashi T, Uemura Y, Kumagai M, Kimpara M, Kanno H, Ohashi Y (2019) MIRACLE-CKD Study Group. Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study). Clin Exp Nephrol 23:349\u2013361. https:\/\/doi.org\/10.1007\/s10157-018-1649-0","journal-title":"Clin Exp Nephrol"},{"key":"2656_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-020-01856-1","author":"Y Ushio","year":"2020","unstructured":"Ushio Y, Kataoka H, Sato M, Manabe S, Watanabe S, Akihisa T, Makabe S, Yoshida R, Tsuchiya K, Nitta K, Mochizuki T (2020) Association between anemia and renal prognosis in autosomal dominant polycystic kidney disease: a retrospective study. Clin Exp Nephrol. https:\/\/doi.org\/10.1007\/s10157-020-01856-1","journal-title":"Clin Exp Nephrol"},{"key":"2656_CR44","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.2215\/CJN.00710113","volume":"8","author":"P Susantitaphong","year":"2013","unstructured":"Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I, Jaber BL (2013) World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol 8:1482\u20131493. https:\/\/doi.org\/10.2215\/CJN.00710113","journal-title":"Clin J Am Soc Nephrol"},{"key":"2656_CR45","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.athoracsur.2013.09.060","volume":"97","author":"R Sickeler","year":"2014","unstructured":"Sickeler R, Phillips-Bute B, Kertai MD, Schroder J, Mathew JP, Swaminathan M, Stafford-Smith M (2014) The risk of acute kidney injury with co-occurrence of anemia and hypotension during cardiopulmonary bypass relative to anemia alone. Ann Thorac Surg 97:865\u2013871. https:\/\/doi.org\/10.1016\/j.athoracsur.2013.09.060","journal-title":"Ann Thorac Surg"},{"key":"2656_CR46","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/liv.14229","volume":"40","author":"B Scheiner","year":"2020","unstructured":"Scheiner B, Semmler G, Maurer F, Schwabl P, Bucsics TA, Paternostro R, Bauer D, Simbrunner B, Trauner M, Mandorfer M, Reiberger T (2020) Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. Liver Int 40:194\u2013204. https:\/\/doi.org\/10.1111\/liv.14229","journal-title":"Liver Int"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02656-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-020-02656-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02656-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T23:35:25Z","timestamp":1635291325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-020-02656-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["2656"],"URL":"https:\/\/doi.org\/10.1007\/s11255-020-02656-y","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"assertion":[{"value":"28 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}